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Abstract
US guidelines provided a permissive recommendation forHPV vaccine for males in 2009, with an
updated recommendation for routine vaccination in 2011. Dataon vaccine uptake among males,
however, remain sparse. We analyzed 2010–2011 data (collected mostlyprior to the
recommendation for routine vaccination) from the National Immunization Survey-Teen for a
nationally representative sample of adolescent males ages 13–17 (n=22,365). We examined HPV
vaccine initiation( receipt of at least one doseba sed on healthcare provider records) as the primary
outcome. Analyses used weighted logistic regression. HPV vaccine initiation increased from 1.4%
in 2010 to 8.3% in 2011. Parents who reported receiving a healthcare provider recommendation to
get their sons HPV vaccine were much more likely to have vaccinated sons (OR=19.02, 95% CI:
14.36–25.19). Initiation was also higher among sons who were Hispanic (OR=1.83, 95% CI: 1.24–
2.71) or who were eligible for the Vaccines for Children program (OR=1.53, 95% CI: 1.01–2.31).
Only31.0% of parents with unvaccinated sons indicatedtheir sons were “somewhat likely” or
“very likely” to receive HPV vaccine in the next year. The most common main reasons for parents
not intending to vaccinate were believing vaccination is not needed or not necessary (24.5%), not
having received a provider recommendation (22.1%), and lack of knowledge (15.9%). HPV
vaccination is low among adolescent males in the US, and provider recommendation for
vaccination is likely keyto improv ingvaccine uptake. Given the updated recommendation for
routine vaccination and the changes in health insurance coverage that are likely to follow,
continued efforts are needed to monitor HPV vaccination among males.
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Introduction
Human papillomavirus (HPV) vaccine offers important health benefits for males.
Quadrivalent HPV vaccine against types 6, 11, 16, and 18 is currently approved by the Food
and Drug Administration (FDA) to prevent genital warts and anal cancer in males [1].
Genital warts are caused primarily by types 6 and 11 [2], and anal cancer is caused primarily
by types 16 and 18 [3]. About 4% of adult males report a prior diagnosis of genital warts [4],
and over 2,000 incident cases of anal cancer occur annually among males [5]. Administering
HPV vaccine to males may also have indirect health benefits for their female partners [6]
due to the high HPV concordance levels among sexual partners [7].
HPV vaccine received its first national recommendation for males in the US in October
2009 [8]. At that time, the Advisory Committee on Immunization Practices (ACIP) provided
a permissive recommendation for administering the three-dose series of quadrivalent
vaccine [8]. The permissive recommendation allowed the vaccine to be administered to
males ages 9–26 but did not make it part of their routine vaccination schedule. The ACIP
strengthened its recommendation in October 2011 by recommending routine HPV
vaccination for males ages 11–12 with catch-up vaccination for males ages 13–21 [9]. The
updated recommendation still allows the vaccine to be given to males as young as age 9 and
through age 26 [9].
Under the permissive recommendation, someprivate health insurance plans covered HPV
vaccine for males, as did the Vaccines for Children (VFC) program [10]. The VFC program
is a federal program that provides vaccines free of charge to children who might not
otherwise be vaccinated because of inability to pay [11]. A child is eligible for the VFC
program if he or she is less than 19 years old and is American Indian or Alaska native,
Medicaid-eligible, uninsured, or underinsured (i.e., insurance does not cover vaccines, does
not cover certain vaccines, or covers vaccines but has a fixed dollar limit or cap for coverage
[after which the child becomes eligible for the VFC program]). Underinsured children are
eligible to receive vaccines only at Federally Qualified Health Centers or Rural Health
Clinics. It is not yet entirely clear how the updated recommendation for routine HPV
vaccination for males has affected insurance coverage of the vaccine by private health
insurance plans, though it is likely that insurance coverage has increased.
Limited data exist on HPV vaccine uptake among males in the US. Initial estimates found
that only about 2% of adolescent males had received any HPV vaccine doses by the end of
2010 [12–14], with a slight increase to about 8% by the end of 2011 [15,16]. Although
several studies have examined correlates of HPV vaccine uptake among adolescent females
[17] and vaccine acceptability for males [14,18–25], only a few studies have identified
correlates of HPV vaccine uptake among adolescent males and reasons why parents are not
vaccinating their sons [13,16,26,27]. We analyzed provider-verified vaccination data from a
nationally representative sample of adolescent males to provide insight into HPV vaccine
uptake among males.
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We used publicly available data from the National Immunization Survey-Teen (NIS-Teen)
[28,29], an annual survey conducted by the Centers for Disease Control and Prevention
(CDC) to monitor vaccination among 13–17 year-olds. The NIS-Teen methodology has
been previously described in great detail [30]. The CDC conducts the NIS-Teen in all 50
states, the District of Columbia, and selected local areas. The NIS-Teen is an add-on to the
National Immunization Survey (NIS), which examines vaccination among children 19–35
months old. Data collection for the NIS-Teen involves two phases: 1) a random-digit-dialed
(RDD) telephone survey with parents/guardians (referred to as “parents”) of adolescents
ages 13–17; and 2) a mailed survey to adolescents’ healthcare providers identified by
parents and for whom consent to contact is obtained. Vaccination estimates are based on
data obtained from provider records [12,15]. The CDC uses a complex stratified sampling
strategy for the NIS-Teen to obtain a national probability sample of adolescents ages 13–17.
For 2010, the RDD sampling frame consisted of only landline telephones, whereas 2011 was
also able to account for cellular telephones [31,32]. The 2011 NIS-Teen dual-frame
sampling approach used independent RDD samples from landline and cellular sampling
frames [32]. If a selected household contains more than one adolescent ages 13–17, one
index adolescent is randomly chosen for the NIS-Teen.
We examined NIS-Teen data from 2010–2011 (all years with HPV vaccination data for
males at the time of analyses) for adolescents with provider-verified vaccination records.
Most data were collected prior to the ACIP providing their recommendation for routine
administration of HPV vaccine to males in October 2011. Datasets included 19,257
adolescents from 2010 (excluding US Virgin Islands; household response rate=58.0% [12])
and 23,564 adolescents from 2011 (excluding US Virgin Islands; household response
rate=57.2% for landline households and 22.4% for cellular households [15]). We report data
on 22,365 adolescent males with provider-verified vaccination records. Data collection for
the NIS-Teen was approved by the National Center for Health Statistics Research Ethics
Review Board. Analysis of deidentified data from the survey is exempt from the federal
regulations for the protection of human research participants. The Institutional Review
Board at The Ohio State University determined this study was exempt from review.
Measures
HPV vaccination status was determined using data from provider-verified vaccination
records. We examined HPV vaccine initiation (receipt of at least one dose of HPV vaccine)
as the primary outcome variable. We focused on initiation because few males have received
any doses of HPV vaccine [15,16,26] and initiation is an appropriate outcome for new health
behaviors [33]. We did, however, characterize HPV vaccine completion (receipt of all three
doses) for descriptive purposes.
Among parents of unvaccinated sons, we examined intent to get their sons HPV vaccine in
the next year. Surveys assessed intent by asking, “How likely is it that [TEEN] will receive
HPV shots in the next 12 months?” Response options included “not likely at all,” “not too
likely,” “not sure/don’t know,” “somewhat likely,” and “very likely” (coded 1–5). Parents
who indicated one of the first three responses were then asked, “What is the main reason
[TEEN] will not receive HPV shots in the next 12 months?” This open-ended item allowed
parents to indicate multiple reasons, which the CDC coded into categories.
Surveys assessed various demographic characteristics (Table 1), which included information
about the son, mother, and household. If someone other than the mother completed the
parent survey, this individual provided information about the mother. Parents provided data
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on health-related characteristics, including whether their sons had visited a healthcare
provider in the last year and their sons’ healthcare coverage. We examined whether sons
were eligible for the VFC program. Surveys also assessed whether parents had ever heard of
HPV and HPV vaccine and if they had ever received a healthcare provider recommendation
to get their sons HPV vaccine.
Data Analysis
We calculated descriptive statistics for HPV vaccine initiation, completion, parents’ intent to
get their sons HPV vaccine in the next year, and parents’ main reasons for not intending to
vaccinate. We used logistic regression to identify correlates of HPV vaccine initiation,
entering all statistically significant bivariate correlates (p<0.05) into a multivariate logistic
regression model. We constructed two multivariate models: 1) one that included whether
parents had received a healthcare provider recommendation to get their sons HPV vaccine;
and 2) one that excluded provider recommendation. We constructed the latter model in
accordance with previous analyses of NIS-Teen data on HPV vaccination among adolescent
females [34]. Both multivariate models controlled for state of residence to account for
unmeasured factors between states that may be important to HPV vaccination. Multivariate
models produced adjusted odds ratios (ORs) and 95% confidence intervals (CIs). We did not
examine parents’ awareness of HPV and HPV vaccine as predictors of vaccination, because
for some parents awareness was likely due to a healthcare provider’s recommendation or
actual vaccination, while for others awareness preceded the provider interaction.
Analyses used sampling weights in determining proportions and effect estimates to account
for the complex design of the NIS-Teen [31,32]. Frequencies are not weighted. We recoded
responses of “don’t know” and “refused” to missing (unless otherwise noted) and excluded
these responses from analyses. Statistical tests were two-tailed with a critical alpha of 0.05.
We used SAS Version 9.2 (Cary, NC) to conduct analyses, including procedures for
analyzing survey data (e.g., PROC SURVEYLOGISTIC). We followed recommended
methods for combining multiple years of NIS-Teen data [32].
Results
Participant Characteristics
The age distribution was fairly even among sons, with each age having at least 19.1% of the
total sample (Table 1). Over half (58.6%) of sons were non-Hispanic white. Most mothers
were 35 years of age or older (90.7%), had at least some college education (60.0%), and
were married (70.2%). A majority of parents had heard of HPV (78.8%) and HPV vaccine
(82.0%), but only 9.9% had received a healthcare provider recommendation to get their sons
HPV vaccine.
HPV Vaccination
For 2010–2011 combined, 4.9% of adolescent males had initiated the HPV vaccine regimen
(Table 2). Only 0.7% of sons had completed the three-dose regimen. HPV vaccine initiation
increased from 1.4% in 2010 to 8.3% in 2011. All variables were correlated with vaccine
initiation in bivariate analyses (Table 2).
In multivariate analyses, healthcare provider recommendation was the strongest correlate of
HPV vaccine initiation (Table 3). Parents who reported receiving a healthcare provider
recommendation to get their sons HPV vaccine were much more likely to have vaccinated
sons (OR=19.02, 95% CI: 14.36–25.19). Initiation was also higher among sons who were
Hispanic (compared to non-Hispanic white sons; OR=1.83, 95% CI: 1.24–2.71), whose
health insurance coverage was not through their parents’ employers or unions (compared to
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sons whose health insurance coverage was through their parents’ employers or unions;
OR=1.61 95% CI: 1.08–2.40), or who were eligible for the VFC program (OR=1.53, 95%
CI: 1.01–2.31). Lastly, the increase in initiation between 2010 and 2011 was statistically
significant (OR=4.38, 95% CI: 3.13–6.12).
When we excluded provider recommendation from the multivariate model, additional
variables became statistically significant (Table 3). HPV vaccine initiation was higher
among sons who had visited their healthcare providers in the last year (OR=1.86, 95% CI:
1.23–2.81), while initiation was lower among sons whose mothers had a high school
education (compared to those whose mothers had less than a high school education;
OR=0.66, 95% CI: 0.45–0.97).
Intent to Vaccinate and Reasons for Not Intending to Vaccinate
Parents with unvaccinated sons reported relatively low levels of intent to vaccinate in the
next year (mean=2.45, standard error [SE]=0.02). Only 31.0% of these parents indicated
their sons were “somewhat likely” or “very likely” to receive HPV vaccine in the next year.
Over half (59.7%) said their sons were “not too likely” or “not likely atall” to receive the
vaccine in the next year, while 9.3% were not sure. Parents’ intent to vaccinate their sons
increased from 2010 (mean=2.37, SE=0.03) to 2011 (mean=2.54, SE=0.03)(p<0.001).
The most common main reasons for parents not intending to vaccinate in the next year were
believing vaccination is not needed or not necessary (24.5%), not having received a provider
recommendation (22.1%), lack of knowledge (15.9%), son not being sexually active
(14.7%), child being male (12.0%), and concerns about vaccine safety or side effects (5.6%)
(Table 4). All other reasons were reported by less than 5.0% of parents.
Discussion
Less than 10% of adolescent males had received any doses of HPV vaccine within the first
years following vaccine licensure for males. Although HPV vaccine initiation increased
from 2010 to 2011, initiation was still much lower than what was observed among
adolescent females in the US following vaccine licensure for them. Initiation among
adolescent females was about 25% within the first year following licensure (2007) and over
30% by the end of the second year (2008) [34–37]. As discussed previously [16], this gender
difference is likely due in part to the ACIP providing different initial recommendations for
vaccination. The ACIP first provided a permissive recommendation for males [8], while
providing the stronger recommendation for routine administration for females [38]. The
ACIP replaced the permissive recommendation and began recommending routine HPV
vaccination for males in October 2011 [9]. Since data collection for the current study
occurred primarily when the permissive recommendation was in place, our results suggest
that the permissive recommendation did not raise vaccine coverage to the extent that the
recommendation for routine provision did for females. Continued surveillance will be
important to monitor the effects of the updated recommendation and any associated changes
in insurance coverage of the vaccine, which may lead to increased vaccine access for males.
Even though the updated recommendation will likely improve HPV vaccine uptake among
males, guidelines alone are likely insufficient to achieve widespread vaccine uptake (similar
to what has been observed among US females [15]). Therefore, additional intervention
strategies will be critically important. One promising intervention strategy will be to
increase healthcare providers’ recommendations to vaccinate [39]. Similar to past research
[16,26], provider recommendation was the strongest correlate of HPV vaccine initiation and
lack of provider recommendation was among the most common reasons for not intending to
vaccinate. Only about 10% of parents in the current study had received a provider
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recommendation, which may be partly attributable to healthcare providers being unsure
about the permissive recommendation and insurance coverage of the vaccine under this
recommendation [40]. However, over 80% of sons had visited a healthcare provider in the
last year, indicating there are many opportunities for provider recommendations to occur.
Visiting a healthcare provider in the last year was also associated with HPV vaccine
initiation, but only in the multivariate model that excluded provider recommendation.
Interventions targeting healthcare providers can help ensure that recommendations are
occurring during healthcare visits. Future studies are needed to determine how the updated
recommendation for routine vaccination and other intervention strategies affect provider
recommendation of HPV vaccine for males.
Efforts are also needed to educate parents and sons about the availability of and need for
vaccinating males against HPV. Research has shown that only about 20% of parents and
10% of sons are aware that HPV vaccine can be given to males [14], and our study suggests
that lack of knowledge continues to be problematic. Many of the most common reasons for
parents not intending to vaccinate involved a perceived lack of knowledge about HPV
vaccine or not recognizing the need to vaccinate males. For this reason, increasing parents’
and sons’ understanding of the importance of HPV vaccine for males is important.
Although HPV vaccination was low overall among adolescent males in the current study,
some findings on health disparities were encouraging. Specifically, initiation was higher
among sons who were Hispanic or eligible for the VFC program. Hispanic males are more
likely to be infected with multiple HPV types compared to non-Hispanic whites [41], while
Hispanic females have the highest cervical cancer incidence rate of any racial or ethnic
group in the US [42]. Vaccinating Hispanics against HPV can therefore have a substantial
public health impact, and our results provide evidence that vaccination is higher among
Hispanic males. This pattern is similar to past studies examining HPV vaccination among
adolescent females and males [13,15]. Our findings also suggest that the VFC Program has
been successful thus far in providing access to HPV vaccine for adolescent males. HPV
vaccine is one of the most expensive vaccines (about $130 per dose [43]), so it is important
that the VFC program is effective in reaching underserved populations. Our results
concerning the VFC program may be partly due to the permissive recommendation, under
which the VFC program covered HPV vaccine for males but some private health insurance
plansdid not[10]. Furthermore, some immunization programs supplied HPV vaccine to
providers specifically to vaccinate VFC-eligible and other underinsured children [40].
Healthcare providers may have thereforebeen less inclinedto vaccinate males with private
health insurance.
Parents with unvaccinated sons reported relatively low levels of intent to vaccinate in the
next year, with only about 30% indicating intent. This estimate is lower than those from
studies conducted prior to or just after the vaccine was first recommended for males [18–
20], when vaccination may have seemed somewhat hypothetical to parents. Our finding is,
however, similar to results from a recent longitudinal study [16]. It is worth noting that
parents’ intent to vaccinate did increase from 2010 to 2011, which differs from the recent
longitudinal study that found vaccine acceptability among parents decreased over time [16].
This inconsistency could be due to a difference in study designs. The NIS-Teen is a serial
cross-sectional survey with an independent sample for each year, whereas the longitudinal
study surveyed the same participants at two timepoints [16]. It remains important to
continue to monitor how parents’ intent to vaccinate their sons against HPV may be
changing over time.
Study strengths include HPV vaccination data based on healthcare provider records for a
large, nationally representative sample of adolescent males. Study limitations include
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differing RDD sampling frame approaches for 2010 and 2011 and household response rates
below 60%. Some parents may have incorrectly recalled whether they had ever received a
provider recommendation to get their sons HPV vaccine. We did not examine correlates of
HPV vaccine completion because so few sons had received all three recommended doses. It
is possible that healthcare provider vaccination records might be incomplete, and the NIS-
Teen did not examine some factors potentially important to HPV vaccine initiation (e.g.,
parents’ health beliefs [44,45]).
Conclusions
HPV vaccine uptake among males was low under the permissive recommendation first
provided for males. Even with the recommendation for routine vaccination of males now in
place, additional intervention strategies will likely still be needed to achieve widespread
HPV vaccine uptake among males. Healthcare providers are a key target for such
interventions, given the importance of provider recommendation to HPV vaccination
behaviors. Future efforts are needed to determine how the updated recommendation,
potential changes in health insurance coverage of the vaccine for males, and other
intervention strategies affect HPV vaccine uptake among males.
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• HPV vaccination is low among adolescent males, with less than 10% vaccinated
• Healthcare provider recommendation is key to increasing HPV vaccination
among males
• Continued efforts are needed to monitor HPV vaccination among males
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Table 1
Characteristics of parents and adolescent sons, 2010–2011 National Immunization Survey-Teen (n=22,365)
n (weighted %)
Year
 2010 10037 (49.6)
 2011 12328 (50.4)
Son characteristics
Age
 13 yr 4573 (19.4)
 14 yr 4582 (19.7)
 15 yr 4488 (20.8)
 16 yr 4584 (21.1)
 17 yr 4138 (19.1)
Race/ethnicity
 White, non-Hispanic 15346 (58.6)
 Black, non-Hispanic 2267 (14.4)
 Other, non-Hispanic 1835 (7.7)
 Hispanic 2917 (19.3)
Visited healthcare provider in last year
 No 3543 (19.0)
 Yes 18690 (81.0)
Healthcare coverage
 Through parent employer or union 14940 (59.0)
 Other insurance, including Medicaid 6102 (33.9)
 No insurance 1183 (7.1)
Eligible for VFC Program
 No 15674 (63.2)
 Yes 6640 (36.8)
Parent characteristics
Mother’s age
 <35 yr 1611 (9.3)
 35–44 yr 9280 (45.0)
 45+ yr 11474 (45.7)
Mother’s education
 Less than high school 2028 (13.4)
 High school 4542 (26.6)
 Some college 6228 (25.5)
 College graduate 9567 (34.5)
Mother’s marital status
 Not married 5380 (29.8)
 Married 16985 (70.2)
Heard of HPVa
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n (weighted %)
 No 3953 (21.2)
 Yes 18030 (78.8)
Heard of HPV vaccinea
 No 2994 (18.0)
 Yes 19128 (82.0)
Received provider recommendation to get son HPV vaccine
 No 19275 (90.1)
 Yes 2381 (9.9)
Household characteristics
Poverty status
 Below poverty 3184 (21.7)
 Above poverty, <$75,000 8802 (42.4)
 Above poverty, >$75,000 9494 (35.9)
Note. Totals may not sum to stated sample size due to missing data. Percents may not sum to 100% due to rounding. HPV=human papillomavirus;
VFC=Vaccines for Children.
a
Among only parents with unvaccinated sons, 78.5% had heard of HPV and 81.7% had heard of HPV vaccine.
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Table 2
HPV vaccination among adolescent males, 2010–2011 National Immunization Survey-Teen (n=22,365)
No. Initiated HPV Vaccine Regimen / Total No. in Category (%) Bivariate OR (95% CI)
Overall 1214/22365 (4.9) --
Year
 2010 169/10037 (1.4) ref.
 2011 1045/12328 (8.3) 6.45 (4.81–8.66)**
Son characteristics
Age
 13 yr 250/4573 (5.6) ref.
 14 yr 244/4582 (4.7) 0.84 (0.60–1.19)
 15 yr 250/4488 (4.5) 0.81 (0.58–1.12)
 16 yr 243/4584 (5.5) 0.99 (0.67–1.45)
 17 yr 227/4138 (3.9) 0.69 (0.49–0.96)*
Race/ethnicity
 White, non-Hispanic 627/15346 (3.3) ref.
 Black, non-Hispanic 160/2267 (5.8) 1.78 (1.34–2.37)**
 Other, non-Hispanic 100/1835 (5.1) 1.56 (1.07–2.27)*
 Hispanic 327/2917 (8.8) 2.81 (2.11–3.74)**
Visited healthcare provider in last year
 No 112/3543 (3.0) ref.
 Yes 1087/18690 (5.3) 1.82 (1.26–2.63)*
Healthcare coverage
 Through parent employer or union 657/14940 (3.1) ref.
 Other insurance, including Medicaid 506/6102 (8.2) 2.75 (2.21–3.43)**
 No insurance 43/1183 (3.5) 1.11 (0.57–2.19)
Eligible for VFC Program
 No 670/15674 (3.2) ref.
 Yes 542/6640 (7.8) 2.57 (2.06–3.21)**
Parent characteristics
Mother’s age
 <35 yr 135/1476 (8.0) ref.
 35–44 yr 556/9280 (5.1) 0.62 (0.44–0.89)*
 45+ yr 523/11474 (3.9) 0.47 (0.32–0.69)**
Mother’s education
 Less than high school 206/2028 (9.2) ref.
 High school 261/4542 (4.5) 0.47 (0.33–0.67)**
 Some college 309/6228 (5.2) 0.55 (0.38–0.79)*
 College graduate 438/9567 (3.2) 0.33 (0.23–0.47)**
Mother’s marital status
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No. Initiated HPV Vaccine Regimen / Total No. in Category (%) Bivariate OR (95% CI)
 Not married 391/5380 (6.3) ref.
 Married 823/16985 (4.2) 0.66 (0.52–0.83)**
Received provider recommendation for HPV vaccine
 No 361/19275 (2.0) ref.
 Yes 808/2381 (30.8) 21.86 (16.95–28.19)**
Household characteristics
Poverty status
 Below poverty 307/3184 (8.9) ref.
 Above poverty, <$75,000 436/8802 (4.8) 0.51 (0.39–0.68)**
 Above poverty, >$75,000 423/9494 (2.8) 0.30 (0.22–0.40)**
Note. HPV = human papillomavirus, No. = number, OR = odds ratio, CI = confidence interval, ref. = referent group, VFC=Vaccines for Children.
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Table 3
Multivariate models for HPV vaccination among adolescent males, 2010–2011 National Immunization
Survey-Teen
Full Model OR (95% CI) Excluding Provider Recommendation OR (95% CI)
Year
 2010 ref. ref.
 2011 4.38 (3.13–6.12)** 6.21 (4.55–8.46)**
Son characteristics
Age
 13 yr ref. ref.
 14 yr 0.76 (0.48–1.22) 0.77 (0.54–1.12)
 15 yr 0.95 (0.62–1.46) 0.80 (0.57–1.14)
 16 yr 0.89 (0.57–1.40) 0.93 (0.64–1.36)
 17 yr 0.90 (0.58–1.38) 0.73 (0.51–1.05)
Race/ethnicity
 White, non-Hispanic ref. ref.
 Black, non-Hispanic 1.26 (0.86–1.86) 1.22 (0.85–1.75)
 Other, non-Hispanic 0.97 (0.59–1.61) 1.07 (0.68–1.68)
 Hispanic 1.83 (1.24–2.71)* 1.90 (1.36–2.65)**
Visited healthcare provider in last year
 No ref. ref.
 Yes 1.64 (0.98–2.74) 1.86 (1.23–2.81)*
Healthcare coverage
 Through parent employer or union ref. ref.
 Other insurance, including Medicaid 1.61 (1.08–2.40)* 1.59 (1.12–2.25)*
 No insurance 0.81 (0.34–1.93) 0.64 (0.31–1.31)
Eligible for VFC Program
 No ref. ref.
 Yes 1.53 (1.01–2.31)* 1.48 (1.05–2.08)*
Parent characteristics
Mother’s age
 <35 yr ref. ref.
 35–44 yr 0.80 (0.50–1.28) 0.88 (0.59–1.31)
 45+ yr 0.91 (0.56–1.47) 0.94 (0.61–1.44)
Mother’s education
 Less than high school ref. ref.
 High school 0.71 (0.43–1.17) 0.66 (0.45–0.97)*
 Some college 0.90 (0.52–1.55) 0.91 (0.60–1.36)
 College graduate 0.78 (0.44–1.37) 0.77 (0.49–1.22)
Mother’s marital status
 Not married ref. ref.
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Full Model OR (95% CI) Excluding Provider Recommendation OR (95% CI)
 Married 1.00 (0.71–1.40) 1.06 (0.79–1.41)
Received provider recommendation for HPV vaccine
 No ref. --
 Yes 19.02 (14.36–25.19)** --
Household characteristics
Poverty status
 Below poverty ref. ref.
 Above poverty, <$75,000 0.93 (0.60–1.43) 0.89 (0.63–1.25)
 Above poverty, >$75,000 0.63 (0.36–1.11) 0.71 (0.44–1.16)
Note. HPV = human papillomavirus, OR = odds ratio, CI = confidence interval, ref. = referent group, VFC=Vaccines for Children. Dashes (--)
indicate that variable was not included in multivariate model. Multivariate models controlled for state of residence. Due to missing data for
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Table 4
Main reasons why parents did not intend to get their adolescent sons HPV vaccine in the next year (n=14,003)
n (weighted %)
Vaccination not needed or not necessary for son 3390 (24.5)
Did not receive healthcare provider recommendation 3039 (22.1)
Lack of knowledge 2058 (15.9)
Son not sexually active 2141 (14.7)
Child is male 1806 (12.0)
Vaccine safety concern/side effects 801 (5.6)
Son not appropriate age 638 (4.2)
Costs 206 (1.7)
No doctor or doctor’s visit not scheduled 188 (1.4)
Family/parent decision 184 (1.1)
Not a school requirement 118 (1.1)
Need more information/new vaccine 140 (1.0)
Son should make decision 89 (0.7)
Son fearful 101 (0.6)
Don’t believe in vaccinations 56 (0.5)
Son handicapped/special needs/illness 66 (0.4)
Vaccine not available 26 (0.1)
Religious beliefs/orthodox 25 (0.1)
Son’s vaccines already up to date 18 (0.1)
Vaccine effectiveness concern 14 (0.1)
Increased sexual activity concern 14 (0.1)
Son will get vaccinated as part of college entry requirements 10 (0.1)
Time 4 (<0.1)
Son already sexually active 2 (<0.1)
Other reason 201 (1.4)
Note. HPV = human papillomavirus. Table includes parents of unvaccinated sons who indicated they were “not likely at all,” “not too likely,” or
“not sure/don’t know” about getting their sons HPV vaccine in the next year.
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